8-K: Zimmer Biomet Raises 2025 EPS Guidance on Strong Q2

Zimmer Biomet reported solid second quarter 2025 financial results, with increased net sales and adjusted earnings per share, leading to a tightened revenue outlook and raised full-year adjusted EPS guidance.

Summary

• Second quarter 2025 net sales reached $2.077 billion, marking a 7.0% increase on a reported basis, 5.4% on a constant currency basis, and 2.8% on an organic constant currency basis compared to the prior year period.
• Diluted earnings per share (GAAP) for Q2 2025 were $0.77, a decrease from $1.18 in Q2 2024.
• Adjusted diluted earnings per share for Q2 2025 increased by 3.0% to $2.07, up from $2.01 in Q2 2024.
• Net earnings (GAAP) for Q2 2025 were $152.8 million, down from $242.8 million in Q2 2024.
• Adjusted net earnings for Q2 2025 were $411.2 million, a slight decrease from $415.0 million in Q2 2024.
• Full-year 2025 reported revenue growth guidance was tightened to 6.7% 7.7%.
• Full-year 2025 constant currency revenue growth guidance was tightened to 6.2% 7.2%.
• Full-year 2025 organic constant currency revenue growth guidance was tightened to 3.5% 4.5%.
• Full-year 2025 adjusted earnings per share financial guidance was increased to $8.10 $8.30, up from the previous range of $7.90 $8.10.
• The company announced a definitive agreement to acquire Monogram Technologies, an AI-driven robotics company.
• A strategic partnership was signed with Getinge to distribute Operating Room capital products to Ambulatory Surgery Center customers.
• Kevin Thornal was appointed as Group President, Global Businesses and the Americas.

Sentiment

Score: 8

Explanation: The filing indicates strong operational performance with increased adjusted EPS and raised full-year guidance, alongside strategic acquisitions and partnerships that position the company for future growth. While GAAP earnings declined due to specific non-recurring costs and higher interest expense, the underlying business momentum and strategic initiatives are positive.

Positives

• Net sales increased by 7.0% on a reported basis to $2.077 billion in Q2 2025, demonstrating strong top-line growth.
• Adjusted diluted earnings per share grew by 3.0% to $2.07 in Q2 2025, indicating improved operational profitability.
• Full-year 2025 adjusted EPS guidance was raised to $8.10 $8.30, signaling increased confidence in future profitability.
• The company tightened its full-year 2025 revenue growth guidance ranges, reflecting greater certainty in its sales outlook.
• Robust new product cycle is driving significant acceleration in U.S. Hips and Knees portfolios.
• Continued strong growth was observed in the global S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic) business.
• The definitive agreement to acquire Monogram Technologies expands the company's robotics suite with semiand fully autonomous solutions, enhancing its competitive position in surgical robotics.
• A strategic partnership with Getinge creates a turnkey solution for Ambulatory Surgery Center customers, potentially expanding market reach.
• The company was named one of America's Best Mid-Size Companies in 2025 by TIME and certified as a Great Place to Work in multiple countries, indicating strong corporate culture and employee satisfaction.

Negatives

• GAAP diluted earnings per share decreased significantly to $0.77 in Q2 2025 from $1.18 in Q2 2024.
• GAAP net earnings decreased to $152.8 million in Q2 2025 from $242.8 million in Q2 2024.
• Operating profit (GAAP) decreased to $300.0 million in Q2 2025 from $351.3 million in Q2 2024.
• Acquisition, integration, divestiture and related expenses increased substantially to $78.9 million in Q2 2025 from $5.2 million in Q2 2024, primarily due to the Paragon 28 acquisition.
• Interest expense, net, increased to $(79.3) million in Q2 2025 from $(51.1) million in Q2 2024, reflecting higher debt levels.
• Long-term debt increased to $6,752.5 million as of June 30, 2025, from $5,341.6 million as of December 31, 2024.

Risks

• Intense competition and pricing pressures in the medical technology market.
• Dependence on successful new product development, technological advances, and innovation.
• Changes in customer demand for products and services due to demographic shifts, obsolescence, or alternative therapies.
• Challenges in attracting, retaining, developing, and maintaining adequate succession plans for highly skilled employees, senior management, independent agents, and distributors.
• Shifts in the product category or regional sales mix of products and services.
• Risks and uncertainties related to the successful execution of restructuring plans.
• Challenges in controlling costs and expenses.
• Risks related to the ability to realize anticipated benefits from acquisitions, including the Paragon 28 acquisition, such as integration difficulties or failure to achieve expected benefits within the timeframe.
• Disruption from acquisitions making it difficult to maintain business and operational relationships with customers, vendors, and service providers.
• Effects of business disruptions affecting the company, its suppliers, customers, or payors.
• Unplanned delays, disruptions, and expenses attributable to enterprise resource planning and other system updates.
• Challenges in forming and implementing strategic alliances.
• Dependence on a limited number of suppliers for key raw materials, other inputs, and outsourced activities.
• Risk of disruptions in the supply of materials and components used in manufacturing or sterilizing products.
• Breaches or failures of information technology systems or products, including cyberattacks, unauthorized access, or theft.
• Unfavorable outcomes of government investigations.
• Impact of healthcare reform and cost containment measures, including reductions in reimbursement levels and repayment demands.
• Impact of substantial indebtedness on the ability to service debt obligations or refinance at maturity.
• Changes in tax obligations arising from examinations by tax authorities and changes in tax laws, including those from the OECD's BEPS project.
• Challenges to the tax-free nature of the ZimVie Inc. spinoff transaction.
• Risk of additional tax liability due to the recategorization of independent agents and distributors to employees.
• Changes in tariffs relating to imports to the U.S. and other countries.
• Risk that material impairment of the carrying value of intangible assets, including goodwill, could negatively affect operating results.
• Changes in general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations.
• Changes in general industry and market conditions, including domestic and international growth, inflation, and currency exchange rates.
• Domestic and international business impact of political, social, and economic instability, tariffs, trade restrictions, embargoes, sanctions, wars, disputes, and other conflicts.
• Challenges relating to changes in and compliance with governmental laws and regulations affecting U.S. and international businesses, including FDA regulations, healthcare fraud and abuse laws, and data privacy and cybersecurity laws.
• The success of quality and operational excellence initiatives.
• Ability to remediate matters identified in inspectional observations issued by the FDA and other regulators while continuing to satisfy product demand.
• Product liability, intellectual property, and commercial litigation losses.
• Ability to obtain and maintain adequate intellectual property protection.

Future Outlook

The company tightened its full-year 2025 reported, constant currency, and organic constant currency revenue growth guidance, while increasing its adjusted earnings per share financial guidance to a range of $8.10 to $8.30. Management anticipates that the robust new product portfolio, including recent innovations in U.S. Hips and Knees, will continue to fuel growth through 2025 and beyond. The acquisition of Monogram Technologies is expected to further expand the company's surgical robotics capabilities, aligning with its long-term strategy of customer-centric innovation.

Management Comments

• "Our team delivered another solid quarter of growth, as our robust new product cycle drove significant acceleration in our U.S. Hips and Knees portfolios and continued strong growth in our global S.E.T. business."
• "We are excited about the early customer enthusiasm and adoption for our broad new product portfolio, which we believe will continue to fuel our growth through 2025 and beyond."
• "Customer-centric innovation like this is central to our long-term strategy, and the recent agreement to acquire Monogram Technologies not only marks a bold step forward in surgical robotics but also exemplifies our commitment to addressing the most meaningful challenges in healthcare."

Industry Context

Zimmer Biomet's performance reflects a dynamic period in the medical technology industry, characterized by increasing demand for advanced surgical solutions, particularly in orthopedics and robotics. The company's focus on new product cycles, strategic acquisitions like Monogram Technologies, and partnerships such as with Getinge, positions it to capitalize on trends towards minimally invasive procedures, personalized medicine, and the growing adoption of robotics in surgical settings. The strong growth in the S.E.T. business aligns with broader industry trends of diversification beyond core joint replacement into high-growth segments. The increased adjusted EPS guidance suggests effective cost management and operational leverage despite inflationary pressures and increased investment in R&D and acquisitions, which are common across the competitive med-tech landscape.

Comparison to Industry Standards

• The 7.0% reported net sales growth for Q2 2025 is competitive within the medical device sector, where many large players are experiencing mid-single-digit to high-single-digit growth driven by elective procedure recovery and innovation.
• The acquisition of Monogram Technologies, an AI-driven robotics company, positions Zimmer Biomet to compete more directly with companies like Stryker (with Mako Robotics) and Johnson & Johnson (with Ottava/VELYS Robotics), aiming to offer a broader and more flexible suite of orthopedic robotics.
• The strategic partnership with Getinge to distribute OR capital products to Ambulatory Surgery Center (ASC) customers is a move to capture growth in the ASC market, a trend seen across the industry as procedures shift from inpatient to outpatient settings for cost efficiency and patient convenience. This strategy is comparable to efforts by other large medical device companies to strengthen their presence in ASCs.
• The increase in adjusted diluted EPS and raised full-year guidance, despite a decline in GAAP EPS due to acquisition-related costs and higher interest expense, indicates a focus on underlying operational performance, a common practice for evaluating mature medical device companies with active M&A strategies.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to raised adjusted EPS guidance, strong sales growth, and strategic acquisitions aimed at long-term value creation, despite a GAAP earnings decline.
• Customers: Enhanced product offerings through new product cycles, expanded robotics solutions via Monogram Technologies acquisition, and turnkey OR solutions through the Getinge partnership, improving patient care and surgical efficiency.
• Employees: Recognition as a 'Great Place to Work' in multiple countries suggests a positive work environment, though ongoing restructuring initiatives could imply some workforce adjustments.
• Creditors: Increased long-term debt due to senior note issuance, which will require ongoing interest payments, but the capital raise supports strategic growth initiatives.

Next Steps

• Integration of Monogram Technologies acquisition to expand robotics suite.
• Continued distribution of Getinge's Operating Room capital products to Ambulatory Surgery Center customers.
• Ongoing execution of the 'This, You Can Do' direct-to-patient campaign for Knee solutions.
• Continued focus on new product cycle to fuel growth through 2025 and beyond.
• Remediation of matters identified in FDA and other regulatory inspectional observations.

Key Dates

Recommendation

The company demonstrated strong operational performance with robust sales growth and a significant increase in adjusted EPS, leading to a raised full-year adjusted EPS guidance. Strategic acquisitions like Monogram Technologies and partnerships with Getinge position Zimmer Biomet for long-term growth in key areas like surgical robotics and ambulatory surgery centers. While GAAP earnings declined due to acquisition-related expenses and higher interest costs, these are largely non-recurring or manageable in the context of strategic expansion. The positive outlook and strategic moves make it an attractive investment for long-term growth.

Keywords

Orthopedics, Medical Technology, Surgical Robotics, Joint Replacement, Knees, Hips, Sports Medicine, Extremities, Trauma, Earnings, Revenue, Guidance, Acquisition, Monogram Technologies, Getinge, Healthcare